ICER conducted a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which examines launch pricing for FDA-approved treatments. This report reviewed the affordability and access of the treatments and their value to the overall health system.

ICER examined all novel drug approvals in the previous 3 years and:

  1. Analyzed list and net price trends
  2. Conducted an in-depth review of drugs that were subject to an ICER analysis
  3. Analyzed affordability and access concerns, such as trends in patient out-of-pocket costs.

For questions please contact [email protected].